Avricore Health Inc. (“AVCR”), announced today a non-brokered private placement of up to 14,285,714 common shares at a price of $0.07 per common share for gross proceeds of up to $1,000,000 (the “Offering”). The Company may pay a finder’s fee on the Offering within the amount permitted by the policies

Avricore Health Inc. (TSX-V: AVCR) (OTCQB: AVCRF) (“Avricore Health” or the “Company”) Dear Shareholders: Thank you for your continued support of Avricore Health. We know this market has been challenging for our industry and our shareholders alike; however, we have had an exciting year and are poised for success in

Avricore Health Inc. Advisory Board Welcomes Hector Bremner Communications professional and former advisor to BC Deputy Premier and Vancouver City Councillor will support Strategic and Government Affairs Avricore Health Inc. (TSXV: AVCR) (“Avricore Health”) is very pleased to announce that Hector Bremner will join the company’s Advisor Board and support

Former Commissioner with the Pharmaceutical Advertising Advisory Board (PAAB) will support strategic marketing practices and ensure strategic direction and regulatory practices. Vancouver, BC / TheNewswire / January 29, 2019 – Avricore Health Inc. (TSXV: AVCR) (“Avricore Health”) is very pleased to announce that Ray Chepesiuk will join the company’s Advisory

VANCOUVER, BC, December 18, 2018 – Avricore Health Inc. (TSXV: AVCR) (“Avricore Health”) is pleased to announce that it has signed a Letter of Intent (LOI) with Molecular You Corporation (“Molecular You”) to distribute Molecular You’s pharmacogenomic tests designed to ensure safe and effective use of cannabis by customers in

VANCOUVER, BC, November 27, 2018 – Avricore Health Inc. (TSXV: AVCR) (“Avricore Health”) is pleased to announce that it has signed a letter of intent to review opportunities to collaborate with FoodRocket to integrate FoodRocket’s precision health offerings and genomics with the HealthTab platform across Canada. Avricore Health is actively

VANCOUVER, BC, November 1, 2018 – VANC Pharmaceuticals Inc. (“VANC”) is excited to announce that further to its news release announced October 25, 2018, the Company has received TSX Venture Exchange approval to change its name (the “Name Change”) to Avricore Health Inc. “We are pleased to have received TSX

VANC Pharmaceuticals Inc. Will Change Its Name to Avricore Health Inc. Reflecting Its New Initiatives and Focus VANCOUVER, BC, October 25, 2018 – VANC Pharmaceuticals Inc. (“VANC”) is pleased to announce that it will seek TSX Venture Exchange (the “TSXV”) approval to change the name of the Company to Avricore

VANCOUVER, BC, September 27, 2018 – VANC Pharmaceuticals Inc. (“VANC”) has contracted with Lampyon Canada Inc. to extend VANC’s proprietary education and ecommerce portal, the Corozon Platform (www.corozonplatform.com), with medical cannabis education and new sales capabilities. Corozon Platform, which is derived from the Latin word for heart, is designed to